Quitting Lilly's obesity drug tirzepatide may be difficult for many patients, exec says

On a day when Eli Lilly revealed stellar trial results for its obesity hopeful tirzepatide and spent more than half of its quarterly earnings presentation discussing the drug's prospects, there was a disquieting side note.